Needham & Company LLC restated their buy rating on shares of Clearside Biomedical (NASDAQ:CLSD - Free Report) in a research report sent to investors on Thursday morning,Benzinga reports. The brokerage currently has a $6.00 target price on the stock.
CLSD has been the topic of a number of other reports. Chardan Capital restated a "buy" rating and set a $6.00 price target on shares of Clearside Biomedical in a report on Friday, November 15th. StockNews.com raised Clearside Biomedical from a "sell" rating to a "hold" rating in a research report on Thursday, December 12th. Finally, HC Wainwright restated a "buy" rating and issued a $6.00 target price on shares of Clearside Biomedical in a research note on Thursday, November 14th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $5.33.
Get Our Latest Research Report on CLSD
Clearside Biomedical Trading Down 5.2 %
CLSD traded down $0.05 during trading on Thursday, reaching $0.88. 236,772 shares of the company's stock were exchanged, compared to its average volume of 381,254. Clearside Biomedical has a one year low of $0.77 and a one year high of $2.12. The stock has a market capitalization of $66.73 million, a PE ratio of -1.96 and a beta of 2.10. The firm has a fifty day moving average price of $0.96 and a two-hundred day moving average price of $1.05.
Institutional Trading of Clearside Biomedical
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Northern Trust Corp grew its stake in shares of Clearside Biomedical by 24.0% during the 4th quarter. Northern Trust Corp now owns 165,499 shares of the company's stock valued at $157,000 after purchasing an additional 32,048 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Clearside Biomedical by 4.5% in the fourth quarter. Geode Capital Management LLC now owns 764,058 shares of the company's stock worth $726,000 after buying an additional 32,672 shares in the last quarter. Investor s Fiduciary Advisor Network LLC bought a new position in shares of Clearside Biomedical during the fourth quarter worth $32,000. Finally, Johnson & Johnson bought a new position in shares of Clearside Biomedical during the third quarter worth $105,000. Hedge funds and other institutional investors own 18.75% of the company's stock.
About Clearside Biomedical
(
Get Free Report)
Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.
Recommended Stories
Before you consider Clearside Biomedical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Clearside Biomedical wasn't on the list.
While Clearside Biomedical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
